Ken Griffin Cel Sci Corp Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$1.11 - $1.85 $11,877 - $19,795	10,700 Added 33.65%	42,500 $49,000
Q1 2024 May 15, 2024	SELL	$1.63 - $3.08 $30,969 - $58,520	-19,000 Reduced 37.4%	31,800 $60,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $3.07 $3,531 - $10,131	-3,300 Reduced 6.1%	50,800 $138,000
Q3 2023 Nov 14, 2023	SELL	$1.17 - $2.86 $15,326 - $37,466	-13,100 Reduced 19.49%	54,100 $67,000
Q2 2023 Aug 14, 2023	BUY	$2.11 - $2.83 $86,088 - $115,464	40,800 Added 154.55%	67,200 $161,000
Q1 2023 May 15, 2023	SELL	$2.17 - $3.13 $154,504 - $222,856	-71,200 Reduced 72.95%	26,400 $61,000
Q4 2022 Feb 14, 2023	SELL	$1.99 - $3.52 $24,278 - $42,944	-12,200 Reduced 11.11%	97,600 $229,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $11,124 - $18,828	-3,600 Reduced 3.17%	109,800 $339,000

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $48.6M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.